ID   RYR1_RABIT              Reviewed;        5037 AA.
AC   P11716;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 1.
DT   22-FEB-2023, entry version 190.
DE   RecName: Full=Ryanodine receptor 1;
DE            Short=RYR-1;
DE            Short=RyR1;
DE   AltName: Full=Skeletal muscle calcium release channel;
DE   AltName: Full=Skeletal muscle ryanodine receptor;
DE   AltName: Full=Skeletal muscle-type ryanodine receptor;
DE   AltName: Full=Type 1 ryanodine receptor;
GN   Name=RYR1;
OS   Oryctolagus cuniculus (Rabbit).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Lagomorpha; Leporidae; Oryctolagus.
OX   NCBI_TaxID=9986;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, DOMAIN, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Skeletal muscle;
RX   PubMed=2725677; DOI=10.1038/339439a0;
RA   Takeshima H., Nishimura S., Matsumoto T., Ishido H., Kangawa K.,
RA   Minamino N., Matsuo H., Ueda M., Hanaoka M., Hirose T., Numa S.;
RT   "Primary structure and expression from complementary DNA of skeletal muscle
RT   ryanodine receptor.";
RL   Nature 339:439-445(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=2298749; DOI=10.1016/s0021-9258(19)39968-5;
RA   Zorzato F., Fujii J., Otsu K., Phillips M.S., Green N.M., Lai F.A.,
RA   Meissner G., Maclennan D.H.;
RT   "Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+
RT   release channel (ryanodine receptor) of skeletal muscle sarcoplasmic
RT   reticulum.";
RL   J. Biol. Chem. 265:2244-2256(1990).
RN   [3]
RP   PROTEIN SEQUENCE OF 3631-3650, S-NITROSYLATION AT CYS-3635, AND INTERACTION
RP   WITH CALM.
RX   PubMed=10601232; DOI=10.1074/jbc.274.52.36831;
RA   Porter Moore C., Zhang J.Z., Hamilton S.L.;
RT   "A role for cysteine 3635 of RYR1 in redox modulation and calmodulin
RT   binding.";
RL   J. Biol. Chem. 274:36831-36834(1999).
RN   [4]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=3722165; DOI=10.1016/s0021-9258(19)84428-9;
RA   Pessah I.N., Francini A.O., Scales D.J., Waterhouse A.L., Casida J.E.;
RT   "Calcium-ryanodine receptor complex. Solubilization and partial
RT   characterization from skeletal muscle junctional sarcoplasmic reticulum
RT   vesicles.";
RL   J. Biol. Chem. 261:8643-8648(1986).
RN   [5]
RP   PHOSPHORYLATION AT SER-2843.
RX   PubMed=8380342; DOI=10.1016/0167-4889(93)90023-i;
RA   Suko J., Maurer-Fogy I., Plank B., Bertel O., Wyskovsky W., Hohenegger M.,
RA   Hellmann G.;
RT   "Phosphorylation of serine 2843 in ryanodine receptor-calcium release
RT   channel of skeletal muscle by cAMP-, cGMP- and CaM-dependent protein
RT   kinase.";
RL   Biochim. Biophys. Acta 1175:193-206(1993).
RN   [6]
RP   INTERACTION WITH FKBP1A, AND TISSUE SPECIFICITY.
RX   PubMed=7669046; DOI=10.1006/bbrc.1995.2283;
RA   Xin H.B., Timerman A.P., Onoue H., Wiederrecht G.J., Fleischer S.;
RT   "Affinity purification of the ryanodine receptor/calcium release channel
RT   from fast twitch skeletal muscle based on its tight association with
RT   FKBP12.";
RL   Biochem. Biophys. Res. Commun. 214:263-270(1995).
RN   [7]
RP   INTERACTION WITH FKBP1A.
RX   PubMed=10603943; DOI=10.1111/j.1749-6632.1998.tb08263.x;
RA   Ondrias K., Marx S.O., Gaburjakova M., Marks A.R.;
RT   "FKBP12 modulates gating of the ryanodine receptor/calcium release
RT   channel.";
RL   Ann. N. Y. Acad. Sci. 853:149-156(1998).
RN   [8]
RP   INTERACTION WITH TRDN.
RX   PubMed=9737879; DOI=10.1021/bi972803d;
RA   Ohkura M., Furukawa K., Fujimori H., Kuruma A., Kawano S., Hiraoka M.,
RA   Kuniyasu A., Nakayama H., Ohizumi Y.;
RT   "Dual regulation of the skeletal muscle ryanodine receptor by triadin and
RT   calsequestrin.";
RL   Biochemistry 37:12987-12993(1998).
RN   [9]
RP   INTERACTION WITH CACNA1S, AND FUNCTION.
RX   PubMed=10388749; DOI=10.1016/s0006-3495(99)76881-5;
RA   Dulhunty A.F., Laver D.R., Gallant E.M., Casarotto M.G., Pace S.M.,
RA   Curtis S.;
RT   "Activation and inhibition of skeletal RyR channels by a part of the
RT   skeletal DHPR II-III loop: effects of DHPR Ser687 and FKBP12.";
RL   Biophys. J. 77:189-203(1999).
RN   [10]
RP   FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, MUTAGENESIS OF
RP   ILE-4897, AND SUBUNIT.
RX   PubMed=10097181; DOI=10.1073/pnas.96.7.4164;
RA   Lynch P.J., Tong J., Lehane M., Mallet A., Giblin L., Heffron J.J.A.,
RA   Vaughan P., Zafra G., MacLennan D.H., McCarthy T.V.;
RT   "A mutation in the transmembrane/luminal domain of the ryanodine receptor
RT   is associated with abnormal Ca(2+) release channel function and severe
RT   central core disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:4164-4169(1999).
RN   [11]
RP   S-NITROSYLATION AT CYS-3635, MUTAGENESIS OF CYS-3635, AND INTERACTION WITH
RP   CALM.
RX   PubMed=11562475; DOI=10.1073/pnas.201289098;
RA   Sun J., Xin C., Eu J.P., Stamler J.S., Meissner G.;
RT   "Cysteine-3635 is responsible for skeletal muscle ryanodine receptor
RT   modulation by NO.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:11158-11162(2001).
RN   [12]
RP   INTERACTION WITH RYR2.
RX   PubMed=12213830; DOI=10.1074/jbc.m208210200;
RA   Xiao B., Masumiya H., Jiang D., Wang R., Sei Y., Zhang L., Murayama T.,
RA   Ogawa Y., Lai F.A., Wagenknecht T., Chen S.R.;
RT   "Isoform-dependent formation of heteromeric Ca2+ release channels
RT   (ryanodine receptors).";
RL   J. Biol. Chem. 277:41778-41785(2002).
RN   [13]
RP   SUBCELLULAR LOCATION, AND MEMBRANE TOPOLOGY.
RX   PubMed=12486242; DOI=10.1073/pnas.012688999;
RA   Du G.G., Sandhu B., Khanna V.K., Guo X.H., MacLennan D.H.;
RT   "Topology of the Ca2+ release channel of skeletal muscle sarcoplasmic
RT   reticulum (RyR1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16725-16730(2002).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   ARG-164; GLY-342; ARG-615; ARG-2163; VAL-2168; ARG-2458 AND THR-4825.
RX   PubMed=12732639; DOI=10.1074/jbc.m302165200;
RA   Yang T., Ta T.A., Pessah I.N., Allen P.D.;
RT   "Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations
RT   associated with malignant hyperthermia and their impact on skeletal
RT   excitation-contraction coupling.";
RL   J. Biol. Chem. 278:25722-25730(2003).
RN   [15]
RP   INTERACTION WITH SELENON.
RX   PubMed=18713863; DOI=10.1073/pnas.0806015105;
RA   Jurynec M.J., Xia R., Mackrill J.J., Gunther D., Crawford T.,
RA   Flanigan K.M., Abramson J.J., Howard M.T., Grunwald D.J.;
RT   "Selenoprotein N is required for ryanodine receptor calcium release channel
RT   activity in human and zebrafish muscle.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12485-12490(2008).
RN   [16]
RP   INTERACTION WITH TRDN AND ASPH.
RX   PubMed=19398037; DOI=10.1016/j.biocel.2009.04.017;
RA   Wei L., Gallant E.M., Dulhunty A.F., Beard N.A.;
RT   "Junctin and triadin each activate skeletal ryanodine receptors but junctin
RT   alone mediates functional interactions with calsequestrin.";
RL   Int. J. Biochem. Cell Biol. 41:2214-2224(2009).
RN   [17]
RP   INTERACTION WITH CACNB1.
RX   PubMed=21320436; DOI=10.1016/j.bpj.2011.01.022;
RA   Rebbeck R.T., Karunasekara Y., Gallant E.M., Board P.G., Beard N.A.,
RA   Casarotto M.G., Dulhunty A.F.;
RT   "The beta(1a) subunit of the skeletal DHPR binds to skeletal RyR1 and
RT   activates the channel via its 35-residue C-terminal tail.";
RL   Biophys. J. 100:922-930(2011).
RN   [18]
RP   FUNCTION, ACTIVITY REGULATION, S-NITROSYLATION AT CYS-3635, AND MUTAGENESIS
RP   OF CYS-3635.
RX   PubMed=22036948; DOI=10.1038/emboj.2011.386;
RA   Kakizawa S., Yamazawa T., Chen Y., Ito A., Murayama T., Oyamada H.,
RA   Kurebayashi N., Sato O., Watanabe M., Mori N., Oguchi K., Sakurai T.,
RA   Takeshima H., Saito N., Iino M.;
RT   "Nitric oxide-induced calcium release via ryanodine receptors regulates
RT   neuronal function.";
RL   EMBO J. 31:417-428(2012).
RN   [19]
RP   INTERACTION WITH SCORPION CALCIN.
RX   PubMed=27114612; DOI=10.1085/jgp.201511499;
RA   Xiao L., Gurrola G.B., Zhang J., Valdivia C.R., SanMartin M., Zamudio F.Z.,
RA   Zhang L., Possani L.D., Valdivia H.H.;
RT   "Structure-function relationships of peptides forming the calcin family of
RT   ryanodine receptor ligands.";
RL   J. Gen. Physiol. 147:375-394(2016).
RN   [20]
RP   STRUCTURE BY ELECTRON MICROSCOPY (10 ANGSTROMS), SUBUNIT, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=15908964; DOI=10.1038/nsmb938;
RA   Samso M., Wagenknecht T., Allen P.D.;
RT   "Internal structure and visualization of transmembrane domains of the RyR1
RT   calcium release channel by cryo-EM.";
RL   Nat. Struct. Mol. Biol. 12:539-544(2005).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 3614-3643 IN COMPLEX WITH CALM.
RX   PubMed=17027503; DOI=10.1016/j.str.2006.08.011;
RA   Maximciuc A.A., Putkey J.A., Shamoo Y., Mackenzie K.R.;
RT   "Complex of calmodulin with a ryanodine receptor target reveals a novel,
RT   flexible binding mode.";
RL   Structure 14:1547-1556(2006).
RN   [22]
RP   STRUCTURE BY ELECTRON MICROSCOPY (9.6 ANGSTROMS), AND SUBUNIT.
RX   PubMed=18621707; DOI=10.1073/pnas.0803189105;
RA   Serysheva I.I., Ludtke S.J., Baker M.L., Cong Y., Topf M., Eramian D.,
RA   Sali A., Hamilton S.L., Chiu W.;
RT   "Subnanometer-resolution electron cryomicroscopy-based domain models for
RT   the cytoplasmic region of skeletal muscle RyR channel.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:9610-9615(2008).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-210.
RX   PubMed=19541610; DOI=10.1073/pnas.0905186106;
RA   Amador F.J., Liu S., Ishiyama N., Plevin M.J., Wilson A., MacLennan D.H.,
RA   Ikura M.;
RT   "Crystal structure of type I ryanodine receptor amino-terminal beta-trefoil
RT   domain reveals a disease-associated mutation 'hot spot' loop.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11040-11044(2009).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 9-205.
RX   PubMed=19913485; DOI=10.1016/j.str.2009.08.016;
RA   Lobo P.A., Van Petegem F.;
RT   "Crystal structures of the N-terminal domains of cardiac and skeletal
RT   muscle ryanodine receptors: insights into disease mutations.";
RL   Structure 17:1505-1514(2009).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-559.
RX   PubMed=21048710; DOI=10.1038/nature09471;
RA   Tung C.C., Lobo P.A., Kimlicka L., Van Petegem F.;
RT   "The amino-terminal disease hotspot of ryanodine receptors forms a
RT   cytoplasmic vestibule.";
RL   Nature 468:585-588(2010).
RN   [26] {ECO:0007744|PDB:3RQR}
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 2733-2940.
RX   PubMed=22913516; DOI=10.1111/j.1742-4658.2012.08755.x;
RA   Sharma P., Ishiyama N., Nair U., Li W., Dong A., Miyake T., Wilson A.,
RA   Ryan T., MacLennan D.H., Kislinger T., Ikura M., Dhe-Paganon S.,
RA   Gramolini A.O.;
RT   "Structural determination of the phosphorylation domain of the ryanodine
RT   receptor.";
RL   FEBS J. 279:3952-3964(2012).
RN   [27] {ECO:0007744|PDB:4ERT, ECO:0007744|PDB:4ESU, ECO:0007744|PDB:4ETU}
RP   X-RAY CRYSTALLOGRAPHY (1.59 ANGSTROMS) OF 2734-2940, AND MUTAGENESIS OF
RP   LEU-2867.
RX   PubMed=22705209; DOI=10.1016/j.str.2012.04.015;
RA   Yuchi Z., Lau K., Van Petegem F.;
RT   "Disease mutations in the ryanodine receptor central region: crystal
RT   structures of a phosphorylation hot spot domain.";
RL   Structure 20:1201-1211(2012).
RN   [28] {ECO:0007744|PDB:4I0Y, ECO:0007744|PDB:4I1E, ECO:0007744|PDB:4I2S, ECO:0007744|PDB:4I37, ECO:0007744|PDB:4I3N, ECO:0007744|PDB:4I6I, ECO:0007744|PDB:4I7I, ECO:0007744|PDB:4I8M, ECO:0007744|PDB:4I96}
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-536.
RX   PubMed=23422674; DOI=10.1038/ncomms2501;
RA   Kimlicka L., Lau K., Tung C.C., Van Petegem F.;
RT   "Disease mutations in the ryanodine receptor N-terminal region couple to a
RT   mobile intersubunit interface.";
RL   Nat. Commun. 4:1506-1506(2013).
RN   [29] {ECO:0007744|PDB:4P9J}
RP   X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS) OF 1070-1246, AND MUTAGENESIS OF
RP   ARG-1076.
RX   PubMed=25370123; DOI=10.1038/ncomms6397;
RA   Lau K., Van Petegem F.;
RT   "Crystal structures of wild type and disease mutant forms of the ryanodine
RT   receptor SPRY2 domain.";
RL   Nat. Commun. 5:5397-5397(2014).
RN   [30] {ECO:0007744|PDB:5C30}
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 857-1054, INTERACTION WITH
RP   FKBP1A, FUNCTION, ACTIVITY REGULATION, AND MUTAGENESIS OF 674-PHE-LEU-675;
RP   ASN-760; ARG-1044; GLY-1050 AND VAL-2461.
RX   PubMed=26245150; DOI=10.1038/ncomms8947;
RA   Yuchi Z., Yuen S.M., Lau K., Underhill A.Q., Cornea R.L., Fessenden J.D.,
RA   Van Petegem F.;
RT   "Crystal structures of ryanodine receptor SPRY1 and tandem-repeat domains
RT   reveal a critical FKBP12 binding determinant.";
RL   Nat. Commun. 6:7947-7947(2015).
RN   [31] {ECO:0007744|PDB:4UWA, ECO:0007744|PDB:4UWE}
RP   STRUCTURE BY ELECTRON MICROSCOPY (6.10 ANGSTROMS), SUBCELLULAR LOCATION,
RP   TOPOLOGY, AND TISSUE SPECIFICITY.
RX   PubMed=25470059; DOI=10.1038/nature13916;
RA   Efremov R.G., Leitner A., Aebersold R., Raunser S.;
RT   "Architecture and conformational switch mechanism of the ryanodine
RT   receptor.";
RL   Nature 517:39-43(2015).
RN   [32] {ECO:0007744|PDB:3J8H}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.80 ANGSTROMS) IN COMPLEX WITH FKBP1A,
RP   SUBUNIT, SUBCELLULAR LOCATION, TOPOLOGY, TISSUE SPECIFICITY, AND DOMAIN.
RX   PubMed=25517095; DOI=10.1038/nature14063;
RA   Yan Z., Bai X.C., Yan C., Wu J., Li Z., Xie T., Peng W., Yin C.C., Li X.,
RA   Scheres S.H., Shi Y., Yan N.;
RT   "Structure of the rabbit ryanodine receptor RyR1 at near-atomic
RT   resolution.";
RL   Nature 517:50-55(2015).
RN   [33] {ECO:0007744|PDB:5T15, ECO:0007744|PDB:5T9M, ECO:0007744|PDB:5T9V, ECO:0007744|PDB:5TA3, ECO:0007744|PDB:5TAL, ECO:0007744|PDB:5TAM, ECO:0007744|PDB:5TAN}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.60 ANGSTROMS) OF 12-1275; 1573-2479;
RP   2734-2939 AND 3639-5037 IN COMPLEXES WITH CALCIUM; ATP; RYANODINE AND
RP   CAFFEINE, FUNCTION, ACTIVITY REGULATION, SUBUNIT, SUBCELLULAR LOCATION,
RP   DOMAIN, AND TOPOLOGY.
RX   PubMed=27662087; DOI=10.1016/j.cell.2016.08.075;
RA   des Georges A., Clarke O.B., Zalk R., Yuan Q., Condon K.J., Grassucci R.A.,
RA   Hendrickson W.A., Marks A.R., Frank J.;
RT   "Structural basis for gating and activation of RyR1.";
RL   Cell 167:145-157(2016).
RN   [34] {ECO:0007744|PDB:5J8V}
RP   STRUCTURE BY ELECTRON MICROSCOPY (4.90 ANGSTROMS), SUBUNIT, SUBCELLULAR
RP   LOCATION, TOPOLOGY, AND TISSUE SPECIFICITY.
RX   PubMed=27573175; DOI=10.1038/cr.2016.99;
RA   Wei R., Wang X., Zhang Y., Mukherjee S., Zhang L., Chen Q., Huang X.,
RA   Jing S., Liu C., Li S., Wang G., Xu Y., Zhu S., Williams A.J., Sun F.,
RA   Yin C.C.;
RT   "Structural insights into Ca(2+)-activated long-range allosteric channel
RT   gating of RyR1.";
RL   Cell Res. 26:977-994(2016).
RN   [35] {ECO:0007744|PDB:5GKY, ECO:0007744|PDB:5GKZ, ECO:0007744|PDB:5GL0, ECO:0007744|PDB:5GL1}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.80 ANGSTROMS) IN COMPLEX WITH FKBP1A,
RP   SUBUNIT, SUBCELLULAR LOCATION, TOPOLOGY, TISSUE SPECIFICITY, AND DOMAIN.
RX   PubMed=27468892; DOI=10.1038/cr.2016.89;
RA   Bai X.C., Yan Z., Wu J., Li Z., Yan N.;
RT   "The central domain of RyR1 is the transducer for long-range allosteric
RT   gating of channel opening.";
RL   Cell Res. 26:995-1006(2016).
CC   -!- FUNCTION: Calcium channel that mediates the release of Ca(2+) from the
CC       sarcoplasmic reticulum into the cytoplasm and thereby plays a key role
CC       in triggering muscle contraction following depolarization of T-tubules
CC       (PubMed:3722165, PubMed:10388749, PubMed:10097181, PubMed:12732639,
CC       PubMed:22036948, PubMed:26245150, PubMed:27662087). Repeated very high-
CC       level exercise increases the open probability of the channel and leads
CC       to Ca(2+) leaking into the cytoplasm (By similarity). Can also mediate
CC       the release of Ca(2+) from intracellular stores in neurons, and may
CC       thereby promote prolonged Ca(2+) signaling in the brain. Required for
CC       normal embryonic development of muscle fibers and skeletal muscle.
CC       Required for normal heart morphogenesis, skin development and
CC       ossification during embryogenesis (By similarity).
CC       {ECO:0000250|UniProtKB:E9PZQ0, ECO:0000269|PubMed:10388749,
CC       ECO:0000269|PubMed:12732639, ECO:0000269|PubMed:22036948,
CC       ECO:0000269|PubMed:27662087, ECO:0000305|PubMed:10097181,
CC       ECO:0000305|PubMed:26245150, ECO:0000305|PubMed:3722165}.
CC   -!- ACTIVITY REGULATION: Channel activity is modulated by the alkaloid
CC       ryanodine that binds to the open Ca-release channel with high affinity
CC       (PubMed:27662087). At low concentrations, ryanodine maintains the
CC       channel in an open conformation (PubMed:27662087). High ryanodine
CC       concentrations inhibit channel activity (PubMed:27662087). Channel
CC       activity is regulated by calmodulin (CALM). The calcium release is
CC       activated by increased cytoplasmic calcium levels, by nitric oxyde
CC       (NO), caffeine and ATP (PubMed:12732639, PubMed:22036948,
CC       PubMed:26245150, PubMed:27662087). Channel activity is inhibited by
CC       magnesium ions, possibly by competition for calcium binding sites
CC       (PubMed:12732639). {ECO:0000269|PubMed:12732639,
CC       ECO:0000269|PubMed:22036948, ECO:0000269|PubMed:26245150,
CC       ECO:0000269|PubMed:27662087}.
CC   -!- SUBUNIT: Homotetramer (PubMed:10097181, PubMed:15908964,
CC       PubMed:17027503, PubMed:18621707, PubMed:25470059, PubMed:25517095,
CC       PubMed:27662087, PubMed:27573175, PubMed:27468892). Can also form
CC       heterotetramers with RYR2 (PubMed:12213830). Identified in a complex
CC       composed of RYR1, PDE4D, PKA, FKBP1A and protein phosphatase 1 (PP1).
CC       Repeated very high-level exercise decreases interaction with PDE4D and
CC       protein phosphatase 1 (PP1) (By similarity). Interacts with CALM; CALM
CC       with bound calcium inhibits the RYR1 channel activity (PubMed:10601232,
CC       PubMed:11562475, PubMed:17027503). Interacts with S100A1 (By
CC       similarity). Interacts with FKBP1A; this stabilizes the closed
CC       conformation of the channel (PubMed:7669046, PubMed:10603943,
CC       PubMed:26245150, PubMed:25517095, PubMed:27468892). Interacts with
CC       CACNA1S; interaction with CACNA1S is important for activation of the
CC       RYR1 channel (PubMed:10388749). Interacts with CACNB1
CC       (PubMed:21320436). Interacts with TRDN and ASPH; these interactions
CC       stimulate RYR1 channel activity (PubMed:9737879, PubMed:19398037).
CC       Interacts with SELENON (PubMed:18713863). Interacts with scorpion
CC       calcins (AC P0DPT1; AC P0DM30; AC A0A1L4BJ42; AC P59868; AC P60254; AC
CC       B8QG00; AC L0GBR1; AC P60252; AC P60253) (PubMed:27114612).
CC       {ECO:0000250|UniProtKB:E9PZQ0, ECO:0000250|UniProtKB:P21817,
CC       ECO:0000269|PubMed:10097181, ECO:0000269|PubMed:10388749,
CC       ECO:0000269|PubMed:10601232, ECO:0000269|PubMed:10603943,
CC       ECO:0000269|PubMed:11562475, ECO:0000269|PubMed:12213830,
CC       ECO:0000269|PubMed:15908964, ECO:0000269|PubMed:17027503,
CC       ECO:0000269|PubMed:18621707, ECO:0000269|PubMed:18713863,
CC       ECO:0000269|PubMed:19398037, ECO:0000269|PubMed:21320436,
CC       ECO:0000269|PubMed:25470059, ECO:0000269|PubMed:25517095,
CC       ECO:0000269|PubMed:26245150, ECO:0000269|PubMed:27468892,
CC       ECO:0000269|PubMed:27573175, ECO:0000269|PubMed:27662087,
CC       ECO:0000269|PubMed:7669046, ECO:0000269|PubMed:9737879}.
CC   -!- INTERACTION:
CC       P11716; P62943: FKBP1A; NbExp=2; IntAct=EBI-6477441, EBI-16134925;
CC       P11716; P11716: RYR1; NbExp=7; IntAct=EBI-6477441, EBI-6477441;
CC       P11716; P28652: Camk2b; Xeno; NbExp=4; IntAct=EBI-6477441, EBI-397029;
CC       P11716; P62942: FKBP1A; Xeno; NbExp=2; IntAct=EBI-6477441, EBI-1027571;
CC       P11716; P68106-1: FKBP1B; Xeno; NbExp=2; IntAct=EBI-6477441, EBI-15766566;
CC       P11716; P02639: S100A1; Xeno; NbExp=3; IntAct=EBI-6477441, EBI-6477285;
CC   -!- SUBCELLULAR LOCATION: Sarcoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:12486242, ECO:0000269|PubMed:25517095,
CC       ECO:0000269|PubMed:2725677, ECO:0000269|PubMed:27468892,
CC       ECO:0000269|PubMed:27573175, ECO:0000269|PubMed:27662087,
CC       ECO:0000269|PubMed:3722165}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:25470059, ECO:0000269|PubMed:25517095,
CC       ECO:0000269|PubMed:27468892, ECO:0000269|PubMed:27573175,
CC       ECO:0000269|PubMed:27662087}. Sarcoplasmic reticulum
CC       {ECO:0000269|PubMed:18713863}. Membrane {ECO:0000269|PubMed:12732639};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:25470059,
CC       ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
CC       ECO:0000269|PubMed:27573175, ECO:0000269|PubMed:27662087}. Note=The
CC       number of predicted transmembrane domains varies between orthologs, but
CC       the 3D-structures show the presence of six transmembrane regions. Both
CC       N-terminus and C-terminus are cytoplasmic.
CC       {ECO:0000269|PubMed:12486242, ECO:0000269|PubMed:25470059,
CC       ECO:0000269|PubMed:27468892, ECO:0000269|PubMed:27573175,
CC       ECO:0000269|PubMed:27662087}.
CC   -!- TISSUE SPECIFICITY: Detected in skeletal muscle (at protein level)
CC       (PubMed:2725677, PubMed:3722165, PubMed:25470059, PubMed:25517095,
CC       PubMed:27573175, PubMed:27468892). Fast- or slow-twitch skeletal
CC       muscle. {ECO:0000269|PubMed:15908964, ECO:0000269|PubMed:25470059,
CC       ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:2725677,
CC       ECO:0000269|PubMed:27468892, ECO:0000269|PubMed:27573175,
CC       ECO:0000269|PubMed:3722165, ECO:0000269|PubMed:7669046}.
CC   -!- DOMAIN: The calcium release channel activity resides in the C-terminal
CC       region while the remaining part of the protein constitutes the 'foot'
CC       structure spanning the junctional gap between the sarcoplasmic
CC       reticulum (SR) and the T-tubule (PubMed:2725677, PubMed:25517095,
CC       PubMed:27662087, PubMed:27573175, PubMed:27468892). Pore opening is
CC       mediated via the cytoplasmic calcium-binding domains that mediate a
CC       small rotation of the channel-forming transmembrane regions that then
CC       leads to channel opening (PubMed:27468892).
CC       {ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:2725677,
CC       ECO:0000269|PubMed:27468892, ECO:0000269|PubMed:27573175,
CC       ECO:0000269|PubMed:27662087}.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- PTM: Channel activity is modulated by phosphorylation. Phosphorylation
CC       at Ser-2843 may increase channel activity. Repeated very high-level
CC       exercise increases phosphorylation at Ser-2843.
CC       {ECO:0000250|UniProtKB:P21817}.
CC   -!- PTM: Activated by reversible S-nitrosylation (PubMed:22036948).
CC       Repeated very high-level exercise increases S-nitrosylation (By
CC       similarity). {ECO:0000250|UniProtKB:P21817,
CC       ECO:0000269|PubMed:22036948}.
CC   -!- MISCELLANEOUS: Coexpression of normal and mutant Thr-4897 RYR1 in a 1:1
CC       ratio produces RYR1 channels with normal halothane and caffeine
CC       sensitivities, but maximal levels of Ca(2+) release are reduced by 67%.
CC       Binding of [3H]ryanodine indicates that the heterozygous channel is
CC       activated by Ca(2+) concentrations 4-fold lower than normal. Single-
CC       cell analysis of cotransfected cells shows a significantly increased
CC       resting cytoplasmic Ca(2+) level and a significantly reduced luminal
CC       Ca(2+) level. These data indicated a leaky channel, possibly caused by
CC       a reduction in the Ca(2+) concentration required for channel
CC       activation. {ECO:0000269|PubMed:10097181}.
CC   -!- SIMILARITY: Belongs to the ryanodine receptor (TC 1.A.3.1) family. RYR1
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X15209; CAA33279.1; -; mRNA.
DR   EMBL; X15750; CAA33762.1; -; mRNA.
DR   PIR; S04654; B35041.
DR   RefSeq; NP_001095188.1; NM_001101718.1.
DR   PDB; 2BCX; X-ray; 2.00 A; B=3614-3643.
DR   PDB; 2XOA; X-ray; 2.50 A; A=1-559.
DR   PDB; 3HSM; X-ray; 2.50 A; A/B=1-210.
DR   PDB; 3ILA; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I=9-205.
DR   PDB; 3J8H; EM; 3.80 A; A/C/E/G=1-5037.
DR   PDB; 3RQR; X-ray; 2.16 A; A=2733-2940.
DR   PDB; 4ERT; X-ray; 1.95 A; A=2734-2940.
DR   PDB; 4ESU; X-ray; 1.59 A; A=2734-2940.
DR   PDB; 4ETT; X-ray; 2.20 A; A=2734-2940.
DR   PDB; 4ETU; X-ray; 2.19 A; A=2734-2938.
DR   PDB; 4I0Y; X-ray; 2.80 A; A=1-536.
DR   PDB; 4I1E; X-ray; 2.40 A; A=1-536.
DR   PDB; 4I2S; X-ray; 2.50 A; A=1-536.
DR   PDB; 4I37; X-ray; 2.95 A; A=1-536.
DR   PDB; 4I3N; X-ray; 2.95 A; A=1-536.
DR   PDB; 4I6I; X-ray; 2.50 A; A=1-559.
DR   PDB; 4I7I; X-ray; 2.90 A; A=1-536.
DR   PDB; 4I8M; X-ray; 2.80 A; A=1-536.
DR   PDB; 4I96; X-ray; 2.73 A; A=217-536.
DR   PDB; 4P9J; X-ray; 1.84 A; A/B/C=1070-1246.
DR   PDB; 4UWA; EM; 6.10 A; A/B/C/D=1-5037.
DR   PDB; 4UWE; EM; 8.50 A; A/B/C/D=1-5037.
DR   PDB; 5C30; X-ray; 1.55 A; A=857-1054.
DR   PDB; 5GKY; EM; 3.80 A; A/C/E/G=1-5037.
DR   PDB; 5GKZ; EM; 4.00 A; A/C/E/G=1-5037.
DR   PDB; 5GL0; EM; 4.20 A; A/C/E/G=1-5037.
DR   PDB; 5GL1; EM; 5.70 A; A/C/E/G=1-5037.
DR   PDB; 5J8V; EM; 4.90 A; A/B/C/D=1-5037.
DR   PDB; 5T15; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-5037.
DR   PDB; 5T9M; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-5037.
DR   PDB; 5T9N; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-5037.
DR   PDB; 5T9R; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-5037.
DR   PDB; 5T9S; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-5037.
DR   PDB; 5T9V; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4540-5037.
DR   PDB; 5TA3; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAL; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAM; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAN; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAP; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAQ; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAS; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAT; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAU; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAV; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAW; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAX; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAY; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TAZ; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TB0; EM; 3.80 A; B/E/G/I=1-5037.
DR   PDB; 5TB1; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TB2; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TB3; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 5TB4; EM; 3.80 A; B/E/G/I=12-1275, B/E/G/I=1573-2479, B/E/G/I=2734-2939, B/E/G/I=3639-4253, B/E/G/I=4541-5037.
DR   PDB; 6FG3; EM; 7.30 A; A/B/C/D=1-5037.
DR   PDB; 6FOO; EM; 8.20 A; A/B/C/D=1-5037.
DR   PDB; 6M2W; EM; 3.80 A; A/D/G/J=1-5037.
DR   PDB; 6WOT; EM; 3.54 A; A/B/C/D=1-5037.
DR   PDB; 7CF9; EM; 4.70 A; A/C/E/G=1-5037.
DR   PDB; 7M6A; EM; 3.36 A; A/B/G/I=1-5037.
DR   PDB; 7M6L; EM; 3.98 A; A/B/G/I=1-5037.
DR   PDB; 7T64; EM; 4.00 A; A/B/C/D=1-5037.
DR   PDB; 7T65; EM; 4.05 A; A/B/C/D=1-5037.
DR   PDB; 7TDG; EM; 3.80 A; A/B/C/D=1-5037.
DR   PDB; 7TDH; EM; 4.00 A; A/B/C/D=1-5037.
DR   PDB; 7TDI; EM; 3.30 A; A/B/C/D=1-5037.
DR   PDB; 7TDJ; EM; 3.70 A; A/B/C/D=1-5037.
DR   PDB; 7TDK; EM; 3.80 A; A/B/C/D=1-5037.
DR   PDB; 7TZC; EM; 2.45 A; A/B/G/I=1-5037.
DR   PDBsum; 2BCX; -.
DR   PDBsum; 2XOA; -.
DR   PDBsum; 3HSM; -.
DR   PDBsum; 3ILA; -.
DR   PDBsum; 3J8H; -.
DR   PDBsum; 3RQR; -.
DR   PDBsum; 4ERT; -.
DR   PDBsum; 4ESU; -.
DR   PDBsum; 4ETT; -.
DR   PDBsum; 4ETU; -.
DR   PDBsum; 4I0Y; -.
DR   PDBsum; 4I1E; -.
DR   PDBsum; 4I2S; -.
DR   PDBsum; 4I37; -.
DR   PDBsum; 4I3N; -.
DR   PDBsum; 4I6I; -.
DR   PDBsum; 4I7I; -.
DR   PDBsum; 4I8M; -.
DR   PDBsum; 4I96; -.
DR   PDBsum; 4P9J; -.
DR   PDBsum; 4UWA; -.
DR   PDBsum; 4UWE; -.
DR   PDBsum; 5C30; -.
DR   PDBsum; 5GKY; -.
DR   PDBsum; 5GKZ; -.
DR   PDBsum; 5GL0; -.
DR   PDBsum; 5GL1; -.
DR   PDBsum; 5J8V; -.
DR   PDBsum; 5T15; -.
DR   PDBsum; 5T9M; -.
DR   PDBsum; 5T9N; -.
DR   PDBsum; 5T9R; -.
DR   PDBsum; 5T9S; -.
DR   PDBsum; 5T9V; -.
DR   PDBsum; 5TA3; -.
DR   PDBsum; 5TAL; -.
DR   PDBsum; 5TAM; -.
DR   PDBsum; 5TAN; -.
DR   PDBsum; 5TAP; -.
DR   PDBsum; 5TAQ; -.
DR   PDBsum; 5TAS; -.
DR   PDBsum; 5TAT; -.
DR   PDBsum; 5TAU; -.
DR   PDBsum; 5TAV; -.
DR   PDBsum; 5TAW; -.
DR   PDBsum; 5TAX; -.
DR   PDBsum; 5TAY; -.
DR   PDBsum; 5TAZ; -.
DR   PDBsum; 5TB0; -.
DR   PDBsum; 5TB1; -.
DR   PDBsum; 5TB2; -.
DR   PDBsum; 5TB3; -.
DR   PDBsum; 5TB4; -.
DR   PDBsum; 6FG3; -.
DR   PDBsum; 6FOO; -.
DR   PDBsum; 6M2W; -.
DR   PDBsum; 6WOT; -.
DR   PDBsum; 7CF9; -.
DR   PDBsum; 7M6A; -.
DR   PDBsum; 7M6L; -.
DR   PDBsum; 7T64; -.
DR   PDBsum; 7T65; -.
DR   PDBsum; 7TDG; -.
DR   PDBsum; 7TDH; -.
DR   PDBsum; 7TDI; -.
DR   PDBsum; 7TDJ; -.
DR   PDBsum; 7TDK; -.
DR   PDBsum; 7TZC; -.
DR   SMR; P11716; -.
DR   BioGRID; 1172559; 3.
DR   ComplexPortal; CPX-3136; Ryanodine 1 complex.
DR   DIP; DIP-41872N; -.
DR   IntAct; P11716; 8.
DR   MINT; P11716; -.
DR   BindingDB; P11716; -.
DR   ChEMBL; CHEMBL3288; -.
DR   iPTMnet; P11716; -.
DR   SwissPalm; P11716; -.
DR   GeneID; 100009540; -.
DR   KEGG; ocu:100009540; -.
DR   CTD; 6261; -.
DR   InParanoid; P11716; -.
DR   OrthoDB; 3144451at2759; -.
DR   EvolutionaryTrace; P11716; -.
DR   PRO; PR:P11716; -.
DR   Proteomes; UP000001811; Unplaced.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0031090; C:organelle membrane; IDA:UniProtKB.
DR   GO; GO:1990425; C:ryanodine receptor complex; IDA:UniProtKB.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0014802; C:terminal cisterna; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0035381; F:ATP-gated ion channel activity; IDA:CAFA.
DR   GO; GO:0005262; F:calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0015278; F:calcium-release channel activity; IMP:AgBase.
DR   GO; GO:0005516; F:calmodulin binding; IDA:BHF-UCL.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005219; F:ryanodine-sensitive calcium-release channel activity; IDA:UniProtKB.
DR   GO; GO:0015643; F:toxic substance binding; IDA:AgBase.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:BHF-UCL.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:InterPro.
DR   GO; GO:0071313; P:cellular response to caffeine; IDA:UniProtKB.
DR   GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB.
DR   GO; GO:0006936; P:muscle contraction; ISS:UniProtKB.
DR   GO; GO:0043931; P:ossification involved in bone maturation; ISS:UniProtKB.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IDA:CAFA.
DR   GO; GO:0014808; P:release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; IMP:UniProtKB.
DR   GO; GO:0048741; P:skeletal muscle fiber development; ISS:UniProtKB.
DR   GO; GO:0043588; P:skin development; ISS:UniProtKB.
DR   CDD; cd12877; SPRY1_RyR; 1.
DR   CDD; cd12878; SPRY2_RyR; 1.
DR   CDD; cd12879; SPRY3_RyR; 1.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.10.490.160; -; 2.
DR   Gene3D; 2.60.120.920; -; 3.
DR   Gene3D; 2.80.10.50; -; 2.
DR   Gene3D; 6.20.350.10; -; 1.
DR   Gene3D; 1.25.10.30; IP3 receptor type 1 binding core, RIH domain; 1.
DR   InterPro; IPR001870; B30.2/SPRY.
DR   InterPro; IPR043136; B30.2/SPRY_sf.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR014821; Ins145_P3_rcpt.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR036300; MIR_dom_sf.
DR   InterPro; IPR016093; MIR_motif.
DR   InterPro; IPR013662; RIH_assoc-dom.
DR   InterPro; IPR000699; RIH_dom.
DR   InterPro; IPR013333; Ryan_recept.
DR   InterPro; IPR015925; Ryanodine_IP3_receptor.
DR   InterPro; IPR003032; Ryanodine_rcpt.
DR   InterPro; IPR009460; Ryanrecept_TM4-6.
DR   InterPro; IPR035910; RyR/IP3R_RIH_dom_sf.
DR   InterPro; IPR035761; SPRY1_RyR.
DR   InterPro; IPR035764; SPRY2_RyR.
DR   InterPro; IPR035762; SPRY3_RyR.
DR   InterPro; IPR003877; SPRY_dom.
DR   PANTHER; PTHR46399; B30.2/SPRY DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR46399:SF10; RYANODINE RECEPTOR 1; 1.
DR   Pfam; PF08709; Ins145_P3_rec; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF02815; MIR; 1.
DR   Pfam; PF08454; RIH_assoc; 1.
DR   Pfam; PF06459; RR_TM4-6; 1.
DR   Pfam; PF01365; RYDR_ITPR; 2.
DR   Pfam; PF02026; RyR; 4.
DR   Pfam; PF00622; SPRY; 3.
DR   PRINTS; PR00795; RYANODINER.
DR   SMART; SM00472; MIR; 4.
DR   SMART; SM00449; SPRY; 3.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 3.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF100909; IP3 receptor type 1 binding core, domain 2; 1.
DR   SUPFAM; SSF82109; MIR domain; 2.
DR   PROSITE; PS50188; B302_SPRY; 3.
DR   PROSITE; PS50919; MIR; 5.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Calcium; Calcium channel; Calcium transport;
KW   Calmodulin-binding; Developmental protein; Direct protein sequencing;
KW   Ion channel; Ion transport; Ligand-gated ion channel; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; S-nitrosylation; Sarcoplasmic reticulum;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..5037
FT                   /note="Ryanodine receptor 1"
FT                   /id="PRO_0000219360"
FT   TOPO_DOM        1..4558
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TRANSMEM        4559..4579
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TOPO_DOM        4580..4640
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TRANSMEM        4641..4661
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TOPO_DOM        4662..4779
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TRANSMEM        4780..4802
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TOPO_DOM        4803
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TRANSMEM        4804..4820
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TOPO_DOM        4821..4835
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TRANSMEM        4836..4856
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TOPO_DOM        4857..4879
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   INTRAMEM        4880..4899
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TOPO_DOM        4900..4919
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TRANSMEM        4920..4940
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   TOPO_DOM        4941..5037
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25470059,
FT                   ECO:0000269|PubMed:25517095, ECO:0000269|PubMed:27468892,
FT                   ECO:0000269|PubMed:27573175"
FT   DOMAIN          98..153
FT                   /note="MIR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          160..205
FT                   /note="MIR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          211..265
FT                   /note="MIR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          271..334
FT                   /note="MIR 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          336..394
FT                   /note="MIR 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          582..798
FT                   /note="B30.2/SPRY 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          842..955
FT                   /note="1"
FT   REPEAT          956..1069
FT                   /note="2"
FT   DOMAIN          1014..1209
FT                   /note="B30.2/SPRY 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          1345..1360
FT                   /note="3; truncated"
FT   DOMAIN          1358..1571
FT                   /note="B30.2/SPRY 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          1373..1388
FT                   /note="4; truncated"
FT   REPEAT          2726..2845
FT                   /note="5"
FT   REPEAT          2846..2959
FT                   /note="6"
FT   DOMAIN          4075..4103
FT                   /note="EF-hand"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448,
FT                   ECO:0000269|PubMed:27573175"
FT   REGION          670..681
FT                   /note="Interaction with FKBP1A"
FT                   /evidence="ECO:0000269|PubMed:26245150"
FT   REGION          842..2959
FT                   /note="6 X approximate repeats"
FT   REGION          1308..1383
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1867..1922
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2390..2412
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2828..2858
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3478..3501
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3614..3643
FT                   /note="Interaction with CALM"
FT   REGION          4252..4282
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4381..4534
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4588..4620
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           4894..4900
FT                   /note="Selectivity filter"
FT                   /evidence="ECO:0000305|PubMed:25517095,
FT                   ECO:0000305|PubMed:27573175, ECO:0000305|PubMed:27662087"
FT   COMPBIAS        1870..1920
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2828..2843
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4255..4270
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4484..4504
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         3893
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305|PubMed:27662087,
FT                   ECO:0007744|PDB:5TA3, ECO:0007744|PDB:5TAL,
FT                   ECO:0007744|PDB:5TAM, ECO:0007744|PDB:5TAN"
FT   BINDING         3967
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305|PubMed:27662087,
FT                   ECO:0007744|PDB:5TA3, ECO:0007744|PDB:5TAL,
FT                   ECO:0007744|PDB:5TAM, ECO:0007744|PDB:5TAN"
FT   BINDING         4211..4215
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|PubMed:27662087,
FT                   ECO:0007744|PDB:5T9V, ECO:0007744|PDB:5TA3,
FT                   ECO:0007744|PDB:5TAL, ECO:0007744|PDB:5TAM,
FT                   ECO:0007744|PDB:5TAN, ECO:0007744|PDB:5TAS,
FT                   ECO:0007744|PDB:5TAT, ECO:0007744|PDB:5TAU"
FT   BINDING         4716
FT                   /ligand="caffeine"
FT                   /ligand_id="ChEBI:CHEBI:27732"
FT                   /evidence="ECO:0000305|PubMed:27662087,
FT                   ECO:0007744|PDB:5TAN"
FT   BINDING         4954..4959
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|PubMed:27662087,
FT                   ECO:0007744|PDB:5T9V, ECO:0007744|PDB:5TA3,
FT                   ECO:0007744|PDB:5TAL, ECO:0007744|PDB:5TAM,
FT                   ECO:0007744|PDB:5TAN, ECO:0007744|PDB:5TAS,
FT                   ECO:0007744|PDB:5TAT, ECO:0007744|PDB:5TAU"
FT   BINDING         4979..4985
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|PubMed:27662087,
FT                   ECO:0007744|PDB:5T9V, ECO:0007744|PDB:5TA3,
FT                   ECO:0007744|PDB:5TAL, ECO:0007744|PDB:5TAM,
FT                   ECO:0007744|PDB:5TAN, ECO:0007744|PDB:5TAS,
FT                   ECO:0007744|PDB:5TAT, ECO:0007744|PDB:5TAU"
FT   BINDING         5001
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305|PubMed:27662087,
FT                   ECO:0007744|PDB:5TA3, ECO:0007744|PDB:5TAL,
FT                   ECO:0007744|PDB:5TAM, ECO:0007744|PDB:5TAN"
FT   MOD_RES         1338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         2345
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         2843
FT                   /note="Phosphoserine; by PKA and PKG"
FT                   /evidence="ECO:0000269|PubMed:8380342"
FT   MOD_RES         3635
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000269|PubMed:10601232,
FT                   ECO:0000269|PubMed:11562475, ECO:0000269|PubMed:22036948"
FT   MOD_RES         4466
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         4470
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         4863
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P21817"
FT   MOD_RES         4866
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P21817"
FT   MUTAGEN         164
FT                   /note="R->C: Decreases threshold for channel activation by
FT                   K(+), caffeine and 4-chloro-m-cresol. Decreases inhibition
FT                   by Mg(2+)."
FT                   /evidence="ECO:0000269|PubMed:12732639"
FT   MUTAGEN         342
FT                   /note="G->R: Decreases threshold for channel activation by
FT                   K(+), caffeine and 4-chloro-m-cresol. Decreases inhibition
FT                   by Mg(2+)."
FT                   /evidence="ECO:0000269|PubMed:12732639"
FT   MUTAGEN         615
FT                   /note="R->C: Decreases threshold for channel activation by
FT                   K(+), caffeine and 4-chloro-m-cresol. Decreases inhibition
FT                   by Mg(2+)."
FT                   /evidence="ECO:0000269|PubMed:12732639"
FT   MUTAGEN         674..675
FT                   /note="FL->AA: Loss of interaction with FKBP1A."
FT                   /evidence="ECO:0000269|PubMed:26245150"
FT   MUTAGEN         760
FT                   /note="N->D: Impairs interaction with FKBP1A."
FT                   /evidence="ECO:0000269|PubMed:26245150"
FT   MUTAGEN         1044
FT                   /note="R->C: Decreases protein stability."
FT                   /evidence="ECO:0000269|PubMed:26245150"
FT   MUTAGEN         1050
FT                   /note="G->S: Decreases protein stability."
FT                   /evidence="ECO:0000269|PubMed:26245150"
FT   MUTAGEN         1076
FT                   /note="R->W: Decreases protein stability."
FT                   /evidence="ECO:0000269|PubMed:25370123"
FT   MUTAGEN         2163
FT                   /note="R->C: Decreases threshold for channel activation by
FT                   K(+), caffeine and 4-chloro-m-cresol. Decreases inhibition
FT                   by Mg(2+)."
FT                   /evidence="ECO:0000269|PubMed:12732639"
FT   MUTAGEN         2168
FT                   /note="V->M: Decreases threshold for channel activation by
FT                   K(+), caffeine and 4-chloro-m-cresol. Decreases inhibition
FT                   by Mg(2+)."
FT                   /evidence="ECO:0000269|PubMed:12732639"
FT   MUTAGEN         2458
FT                   /note="R->H: Decreases threshold for channel activation by
FT                   K(+), caffeine and 4-chloro-m-cresol. Decreases inhibition
FT                   by Mg(2+)."
FT                   /evidence="ECO:0000269|PubMed:12732639"
FT   MUTAGEN         2461
FT                   /note="V->G: Impairs interaction with FKBP1A."
FT                   /evidence="ECO:0000269|PubMed:26245150"
FT   MUTAGEN         2867
FT                   /note="L->G: Decreases protein stability."
FT                   /evidence="ECO:0000269|PubMed:22705209"
FT   MUTAGEN         3635
FT                   /note="C->A: Abolishes S-nitrosocysteine formation."
FT                   /evidence="ECO:0000269|PubMed:11562475,
FT                   ECO:0000269|PubMed:22036948"
FT   MUTAGEN         4825
FT                   /note="T->I: Decreases threshold for channel activation by
FT                   K(+), caffeine and 4-chloro-m-cresol. Decreases inhibition
FT                   by Mg(2+)."
FT                   /evidence="ECO:0000269|PubMed:12732639"
FT   MUTAGEN         4897
FT                   /note="I->T: Loss of channel activation by halothane and
FT                   caffeine due to Ca(2+) store depletion, probably due to
FT                   constant Ca(2+) leakage through the mutant channel."
FT                   /evidence="ECO:0000269|PubMed:10097181"
FT   CONFLICT        2015
FT                   /note="E -> D (in Ref. 2; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3481..3485
FT                   /note="Missing (in Ref. 2; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   STRAND          19..28
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          31..38
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          42..44
FT                   /evidence="ECO:0007829|PDB:3HSM"
FT   STRAND          48..51
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            53..57
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            63..65
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          67..73
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           75..83
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          106..111
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            112..114
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          117..120
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          133..140
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           144..146
FT                   /evidence="ECO:0007829|PDB:4I6I"
FT   STRAND          147..154
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          164..166
FT                   /evidence="ECO:0007829|PDB:3ILA"
FT   STRAND          168..173
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            174..176
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          179..183
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          186..188
FT                   /evidence="ECO:0007829|PDB:4I8M"
FT   STRAND          190..196
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          200..206
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          219..223
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          225..233
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            239..242
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          245..250
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           251..254
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           256..258
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          260..265
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            268..271
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          280..284
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            285..287
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          290..294
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            295..297
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          298..302
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           304..306
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           309..312
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          314..319
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          332..334
FT                   /evidence="ECO:0007829|PDB:2XOA"
FT   TURN            341..343
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          346..350
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            351..353
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          356..359
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          373..381
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          388..392
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           395..420
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   TURN            421..423
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           438..451
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           461..480
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           483..494
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   STRAND          497..499
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           500..504
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           509..512
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           515..530
FT                   /evidence="ECO:0007829|PDB:4I1E"
FT   HELIX           865..867
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   HELIX           868..888
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   TURN            899..902
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   HELIX           910..912
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   HELIX           915..934
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   STRAND          939..941
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   HELIX           946..949
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   HELIX           957..959
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   HELIX           979..990
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   STRAND          994..997
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   TURN            998..1001
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   STRAND          1002..1005
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   STRAND          1021..1023
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   HELIX           1024..1026
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   HELIX           1029..1048
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   STRAND          1051..1053
FT                   /evidence="ECO:0007829|PDB:5C30"
FT   STRAND          1073..1075
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   HELIX           1079..1081
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   STRAND          1083..1096
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   STRAND          1098..1105
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   STRAND          1121..1125
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   TURN            1126..1129
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   STRAND          1130..1140
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   STRAND          1148..1154
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   TURN            1155..1158
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   STRAND          1159..1164
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   STRAND          1178..1181
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   STRAND          1188..1194
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   STRAND          1200..1203
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   HELIX           1208..1210
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   TURN            1214..1222
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   HELIX           1226..1229
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   HELIX           1242..1244
FT                   /evidence="ECO:0007829|PDB:4P9J"
FT   HELIX           2749..2751
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   HELIX           2752..2772
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   TURN            2783..2786
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   HELIX           2794..2796
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   HELIX           2799..2818
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   STRAND          2822..2825
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   HELIX           2862..2864
FT                   /evidence="ECO:0007829|PDB:4ETT"
FT   HELIX           2869..2897
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   HELIX           2908..2910
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   HELIX           2913..2932
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   STRAND          2935..2938
FT                   /evidence="ECO:0007829|PDB:4ESU"
FT   HELIX           3617..3638
FT                   /evidence="ECO:0007829|PDB:2BCX"
SQ   SEQUENCE   5037 AA;  565253 MW;  4ABD87AA26697070 CRC64;
     MGDGGEGEDE VQFLRTDDEV VLQCSATVLK EQLKLCLAAE GFGNRLCFLE PTSNAQNVPP
     DLAICCFTLE QSLSVRALQE MLANTVEAGV ESSQGGGHRT LLYGHAILLR HAHSRMYLSC
     LTTSRSMTDK LAFDVGLQED ATGEACWWTM HPASKQRSEG EKVRVGDDLI LVSVSSERYL
     HLSTASGELQ VDASFMQTLW NMNPICSCCE EGYVTGGHVL RLFHGHMDEC LTISAADSDD
     QRRLVYYEGG AVCTHARSLW RLEPLRISWS GSHLRWGQPL RIRHVTTGRY LALTEDQGLV
     VVDACKAHTK ATSFCFRVSK EKLDTAPKRD VEGMGPPEIK YGESLCFVQH VASGLWLTYA
     APDPKALRLG VLKKKAILHQ EGHMDDALFL TRCQQEESQA ARMIHSTAGL YNQFIKGLDS
     FSGKPRGSGP PAGPALPIEA VILSLQDLIG YFEPPSEELQ HEEKQSKLRS LRNRQSLFQE
     EGMLSLVLNC IDRLNVYTTA AHFAEYAGEE AAESWKEIVN LLYELLASLI RGNRANCALF
     STNLDWVVSK LDRLEASSGI LEVLYCVLIE SPEVLNIIQE NHIKSIISLL DKHGRNHKVL
     DVLCSLCVCN GVAVRSNQDL ITENLLPGRE LLLQTNLINY VTSIRPNIFV GRAEGSTQYG
     KWYFEVMVDE VVPFLTAQAT HLRVGWALTE GYSPYPGGGE GWGGNGVGDD LYSYGFDGLH
     LWTGHVARPV TSPGQHLLAP EDVVSCCLDL SVPSISFRIN GCPVQGVFEA FNLDGLFFPV
     VSFSAGVKVR FLLGGRHGEF KFLPPPGYAP CHEAVLPRER LRLEPIKEYR REGPRGPHLV
     GPSRCLSHTD FVPCPVDTVQ IVLPPHLERI REKLAENIHE LWALTRIEQG WTYGPVRDDN
     KRLHPCLVNF HSLPEPERNY NLQMSGETLK TLLALGCHVG MADEKAEDNL KKTKLPKTYM
     MSNGYKPAPL DLSHVRLTPA QTTLVDRLAE NGHNVWARDR VAQGWSYSAV QDIPARRNPR
     LVPYRLLDEA TKRSNRDSLC QAVRTLLGYG YNIEPPDQEP SQVENQSRWD RVRIFRAEKS
     YTVQSGRWYF EFEAVTTGEM RVGWARPELR PDVELGADEL AYVFNGHRGQ RWHLGSEPFG
     RPWQSGDVVG CMIDLTENTI IFTLNGEVLM SDSGSETAFR EIEIGDGFLP VCSLGPGQVG
     HLNLGQDVSS LRFFAICGLQ EGFEPFAINM QRPVTTWFSK SLPQFEPVPP EHPHYEVARM
     DGTVDTPPCL RLAHRTWGSQ NSLVEMLFLR LSLPVQFHQH FRCTAGATPL APPGLQPPAE
     DEARAAEPDP DYENLRRSAG GWGEAEGGKE GTAKEGTPGG TPQPGVEAQP VRAENEKDAT
     TEKNKKRGFL FKAKKAAMMT QPPATPALPR LPHDVVPADN RDDPEIILNT TTYYYSVRVF
     AGQEPSCVWV GWVTPDYHQH DMNFDLSKVR AVTVTMGDEQ GNVHSSLKCS NCYMVWGGDF
     VSPGQQGRIS HTDLVIGCLV DLATGLMTFT ANGKESNTFF QVEPNTKLFP AVFVLPTHQN
     VIQFELGKQK NIMPLSAAMF LSERKNPAPQ CPPRLEVQML MPVSWSRMPN HFLQVETRRA
     GERLGWAVQC QDPLTMMALH IPEENRCMDI LELSERLDLQ RFHSHTLRLY RAVCALGNNR
     VAHALCSHVD QAQLLHALED AHLPGPLRAG YYDLLISIHL ESACRSRRSM LSEYIVPLTP
     ETRAITLFPP GRKGGNARRH GLPGVGVTTS LRPPHHFSPP CFVAALPAAG VAEAPARLSP
     AIPLEALRDK ALRMLGEAVR DGGQHARDPV GGSVEFQFVP VLKLVSTLLV MGIFGDEDVK
     QILKMIEPEV FTEEEEEEEE EEEEEEEEEE DEEEKEEDEE EEEKEDAEKE EEEAPEGEKE
     DLEEGLLQMK LPESVKLQMC NLLEYFCDQE LQHRVESLAA FAERYVDKLQ ANQRSRYALL
     MRAFTMSAAE TARRTREFRS PPQEQINMLL HFKDEADEED CPLPEDIRQD LQDFHQDLLA
     HCGIQLEGEE EEPEEETSLS SRLRSLLETV RLVKKKEEKP EEELPAEEKK PQSLQELVSH
     MVVRWAQEDY VQSPELVRAM FSLLHRQYDG LGELLRALPR AYTISPSSVE DTMSLLECLG
     QIRSLLIVQM GPQEENLMIQ SIGNIMNNKV FYQHPNLMRA LGMHETVMEV MVNVLGGGET
     KEIRFPKMVT SCCRFLCYFC RISRQNQRSM FDHLSYLLEN SGIGLGMQGS TPLDVAAASV
     IDNNELALAL QEQDLEKVVS YLAGCGLQSC PMLLAKGYPD IGWNPCGGER YLDFLRFAVF
     VNGESVEENA NVVVRLLIRK PECFGPALRG EGGSGLLAAI EEAIRISEDP ARDGPGVRRD
     RRREHFGEEP PEENRVHLGH AIMSFYAALI DLLGRCAPEM HLIQAGKGEA LRIRAILRSL
     VPLDDLVGII SLPLQIPTLG KDGALVQPKM SASFVPDHKA SMVLFLDRVY GIENQDFLLH
     VLDVGFLPDM RAAASLDTAT FSTTEMALAL NRYLCLAVLP LITKCAPLFA GTEHRAIMVD
     SMLHTVYRLS RGRSLTKAQR DVIEDCLMAL CRYIRPSMLQ HLLRRLVFDV PILNEFAKMP
     LKLLTNHYER CWKYYCLPTG WANFGVTSEE ELHLTRKLFW GIFDSLAHKK YDQELYRMAM
     PCLCAIAGAL PPDYVDASYS SKAEKKATVD AEGNFDPRPV ETLNVIIPEK LDSFINKFAE
     YTHEKWAFDK IQNNWSYGEN VDEELKTHPM LRPYKTFSEK DKEIYRWPIK ESLKAMIAWE
     WTIEKAREGE EERTEKKKTR KISQTAQTYD PREGYNPQPP DLSGVTLSRE LQAMAEQLAE
     NYHNTWGRKK KQELEAKGGG THPLLVPYDT LTAKEKARDR EKAQELLKFL QMNGYAVTRG
     LKDMELDTSS IEKRFAFGFL QQLLRWMDIS QEFIAHLEAV VSSGRVEKSP HEQEIKFFAK
     ILLPLINQYF TNHCLYFLST PAKVLGSGGH ASNKEKEMIT SLFCKLAALV RHRVSLFGTD
     APAVVNCLHI LARSLDARTV MKSGPEIVKA GLRSFFESAS EDIEKMVENL RLGKVSQART
     QVKGVGQNLT YTTVALLPVL TTLFQHIAQH QFGDDVILDD VQVSCYRTLC SIYSLGTTKN
     TYVEKLRPAL GECLARLAAA MPVAFLEPQL NEYNACSVYT TKSPRERAIL GLPNSVEEMC
     PDIPVLDRLM ADIGGLAESG ARYTEMPHVI EITLPMLCSY LPRWWERGPE APPPALPAGA
     PPPCTAVTSD HLNSLLGNIL RIIVNNLGID EATWMKRLAV FAQPIVSRAR PELLHSHFIP
     TIGRLRKRAG KVVAEEEQLR LEAKAEAEEG ELLVRDEFSV LCRDLYALYP LLIRYVDNNR
     AHWLTEPNAN AEELFRMVGE IFIYWSKSHN FKREEQNFVV QNEINNMSFL TADSKSKMAK
     AGDAQSGGSD QERTKKKRRG DRYSVQTSLI VATLKKMLPI GLNMCAPTDQ DLIMLAKTRY
     ALKDTDEEVR EFLQNNLHLQ GKVEGSPSLR WQMALYRGLP GREEDADDPE KIVRRVQEVS
     AVLYHLEQTE HPYKSKKAVW HKLLSKQRRR AVVACFRMTP LYNLPTHRAC NMFLESYKAA
     WILTEDHSFE DRMIDDLSKA GEQEEEEEEV EEKKPDPLHQ LVLHFSRTAL TEKSKLDEDY
     LYMAYADIMA KSCHLEEGGE NGEAEEEEVE VSFEEKEMEK QRLLYQQSRL HTRGAAEMVL
     QMISACKGET GAMVSSTLKL GISILNGGNA EVQQKMLDYL KDKKEVGFFQ SIQALMQTCS
     VLDLNAFERQ NKAEGLGMVN EDGTVINRQN GEKVMADDEF TQDLFRFLQL LCEGHNNDFQ
     NYLRTQTGNT TTINIIICTV DYLLRLQESI SDFYWYYSGK DVIEEQGKRN FSKAMSVAKQ
     VFNSLTEYIQ GPCTGNQQSL AHSRLWDAVV GFLHVFAHMM MKLAQDSSQI ELLKELLDLQ
     KDMVVMLLSL LEGNVVNGMI ARQMVDMLVE SSSNVEMILK FFDMFLKLKD IVGSEAFQDY
     VTDPRGLISK KDFQKAMDSQ KQFTGPEIQF LLSCSEADEN EMINFEEFAN RFQEPARDIG
     FNVAVLLTNL SEHVPHDPRL RNFLELAESI LEYFRPYLGR IEIMGASRRI ERIYFEISET
     NRAQWEMPQV KESKRQFIFD VVNEGGEAEK MELFVSFCED TIFEMQIAAQ ISEPEGEPEA
     DEDEGMGEAA AEGAEEGAAG AEGAAGTVAA GATARLAAAA ARALRGLSYR SLRRRVRRLR
     RLTAREAATA LAALLWAVVA RAGAAGAGAA AGALRLLWGS LFGGGLVEGA KKVTVTELLA
     GMPDPTSDEV HGEQPAGPGG DADGAGEGEG EGDAAEGDGD EEVAGHEAGP GGAEGVVAVA
     DGGPFRPEGA GGLGDMGDTT PAEPPTPEGS PILKRKLGVD GEEEELVPEP EPEPEPEPEK
     ADEENGEKEE VPEAPPEPPK KAPPSPPAKK EEAGGAGMEF WGELEVQRVK FLNYLSRNFY
     TLRFLALFLA FAINFILLFY KVSDSPPGED DMEGSAAGDL AGAGSGGGSG WGSGAGEEAE
     GDEDENMVYY FLEESTGYME PALWCLSLLH TLVAFLCIIG YNCLKVPLVI FKREKELARK
     LEFDGLYITE QPGDDDVKGQ WDRLVLNTPS FPSNYWDKFV KRKVLDKHGD IFGRERIAEL
     LGMDLASLEI TAHNERKPDP PPGLLTWLMS IDVKYQIWKF GVIFTDNSFL YLGWYMVMSL
     LGHYNNFFFA AHLLDIAMGV KTLRTILSSV THNGKQLVMT VGLLAVVVYL YTVVAFNFFR
     KFYNKSEDED EPDMKCDDMM TCYLFHMYVG VRAGGGIGDE IEDPAGDEYE LYRVVFDITF
     FFFVIVILLA IIQGLIIDAF GELRDQQEQV KEDMETKCFI CGIGSDYFDT TPHGFETHTL
     EEHNLANYMF FLMYLINKDE TEHTGQESYV WKMYQERCWD FFPAGDCFRK QYEDQLS
//
